Visão geral da empresa
A clinical-stage biotechnology firm, Tenaya Therapeutics, Inc. focuses on the discovery, development, and delivery of specialized therapies targeting heart disease within the United States market. The company operates within the broader Healthcare sector, specifically navigating the competitive and high-risk landscape of the Biotechnology industry where success depends on advancing novel treatments through rigorous clinical trials. Tenaya Therapeutics currently maintains a market capitalization of $157.37M and employs approximately 70 individuals to support its research and development efforts. While the company reports N/A for annual revenue due to its clinical-stage status, the market cap of $157.37M reflects significant investor capitalization on its pipeline potential rather than current operational cash flows. This valuation indicates that the market is pricing the company based on the expected future value of its lead product candidates, such as TN-201, which is in Phase 1b/2 trials for hypertrophic cardiomyopathy, rather than existing sales performance.
Saúde financeira
Tenaya Therapeutics reports N/A for revenue and net income figures for the trailing twelve months, alongside an EBITDA of $-84,895,000, which collectively reveal a cost structure dominated by research and development expenditures rather than commercial sales operations. The company generates a free cash flow of $-37,358,876, indicating a substantial cash outflow that limits immediate financial flexibility and necessitates reliance on external capital sources to fund ongoing clinical programs. All three margins—gross margin at 0.0%, operating margin at 0.0%, and profit margin at 0.0%—are zero, a standard characteristic for early-stage biotechnology firms that have not yet achieved commercial product revenue. The balance sheet holds $100.55M in cash against $10.83M in debt, resulting in a debt-to-equity ratio of 8.79, which suggests a leveraged position where equity dilution is a more likely mechanism for refinancing than traditional debt reduction. Despite the high leverage ratio, the current ratio stands at 6.84, demonstrating robust short-term liquidity provided by the substantial cash reserves relative to current liabilities. However, the return on equity is -83.8% and the return on assets is -43.7%, metrics that indicate management is currently eroding shareholder value through significant losses incurred during the development phase rather than generating returns on invested capital.
Avaliação de valorização
The trailing P/E ratio is N/A due to the absence of net income, while the forward P/E is listed at -1.60, a metric that implies negative expected earnings trajectory or a valuation model based on anticipated losses in the coming period. The price-to-book ratio is 1.27, indicating that the market values the company at a 27% premium over its net asset book value, reflecting confidence in the intangible value of its intellectual property and clinical pipeline. The price-to-sales ratio is N/A and the EV/EBITDA is -0.80, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable, and the valuation relies heavily on the underlying cash position and potential future milestones. The 52-week price range spans from a low of $0.36 to a high of $2.35, placing the current trading price well below the 52-week high and indicating significant price volatility over the past year. The stock exhibits a beta of 3.00, which means the share price is expected to fluctuate with three times the volatility of the broader market, exposing investors to heightened risk during periods of general market correction.
Growth & Income
Tenaya Therapeutics reports N/A for both revenue growth and earnings growth year-over-year, as the company has not yet generated commercial sales to establish a historical growth baseline for comparison. Because the company is in a pre-revenue stage, the concept of a sustainable dividend yield is not applicable, and the payout ratio is recorded at 0.0%, confirming that the firm retains all available capital to fund its operations rather than distributing income to shareholders. The absence of a dividend yield aligns with the company's strategy of reinvesting all available resources, including its $100.55M cash reserve, directly into the advancement of its gene therapy pipeline and clinical trials. Consequently, the overall growth and income profile is characterized by zero current earnings generation and zero dividend distribution, with value creation entirely dependent on the successful execution of its clinical development roadmap and the eventual commercialization of TN-201.